title: Principles of cost effectiveness analysis for the assessment of current and new therapies.
abstract: Economic issues have a prominent place in the debate about reforming the U.S. health care system. If more rational allocations of health care resources are to occur, the principles of decision analysis and clinical economics will need to be understood and used to assess current and new technologies. This requires an explicit assessment of the costs and benefits of a health care intervention, defining the current standard intervention, and clarifying the perspective of the assessment (societal, patient, payer, or provider). Detailed cost accounting of resources is optimal in contrast to costs or charges. These principles were included in 1992 proposed Canadian guidelines for using economic evaluations for adoption of new technologies. Such guidelines provide further impetus for the economic assessment of phase III clinical trials. When applied to peripheral blood progenitor cells, future studies should assess the incremental benefits of the strategy using the progenitor cells, not just the cost savings compared to traditional autologous bone marrow transplantation.
authors.affiliation: Massey Cancer Center, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
authors.forename: B E
authors.initials: BE
authors.lastname: Hillner
authors.forename: T J
authors.initials: TJ
authors.lastname: Smith
authors.forename: C E
authors.initials: CE
authors.lastname: Desch
mesh_terms: D002170:Canada; D017326:Clinical Trials, Phase III as Topic; D003363:Cost Control; D003362:Cost-Benefit Analysis; D017408:Guidelines as Topic; D017048:Health Care Costs; D006295:Health Resources / Q000191:economics; D013673:Technology Assessment, Biomedical; D013675:Technology, High-Cost; D013812:Therapeutics / Q000191:economics*